Integra LifeSciences
IART
256 hedge funds and large institutions have $5.1B invested in Integra LifeSciences in 2021 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 68 increasing their positions, 104 reducing their positions, and 26 closing their positions.
31% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 26
6% more capital invested
Capital invested by funds: $4.81B → $5.1B (+$288M)
2% more funds holding
Funds holding: 251 → 256 (+5)
4% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $11.9M
0.46% less ownership
Funds ownership: 87.97% → 87.5% (-0.46%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
35% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 104
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$16.6M |
| 2 |
Goldman Sachs
New York
|
+$16.2M |
| 3 |
Millennium Management
New York
|
+$14.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9M |
| 5 |
BlackRock
New York
|
+$7.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$12.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.5M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$7.86M |
| 4 |
TCM
Tributary Capital Management
Omaha,
Nebraska
|
-$7.53M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$6.78M |
IART Hedge Fund Activity: Q1 2021 in Review
256 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q1 2021, worth a combined $5.1B — up 6% from $4.81B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new IART positions and 26 closed out — a net gain of 8 holders — while 68 added to existing stakes and 104 trimmed.
The largest buyer was Eaton Vance Management, adding an estimated $16.6M. The largest seller was Capital International Investors, exiting entirely with an estimated $12.5M sold.
- 256 institutional investors held Integra LifeSciences (IART) as of Q1 2021, up from 251 in Q4 2020.
- Funds reported $5.1B of Integra LifeSciences stock for Q1 2021, up 6% quarter-over-quarter.
- 34 funds opened new Integra LifeSciences positions in Q1 2021 and 26 closed out, a net change of +8 holders.
- The largest Integra LifeSciences buyer in Q1 2021 was Eaton Vance Management, an estimated $16.6M added.
- The largest Integra LifeSciences seller in Q1 2021 was Capital International Investors, an estimated $12.5M sold.
Based on aggregated 13F filings for Q1 2021.